| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C21orf7 |
| Uniprot No | P57077 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-142aa |
| 氨基酸序列 | MISTARVPADKPVRIAFSLNDASDDTPPEDSIPLVFPELDQQLQPLPPCHDSEESMEVFKQHCQIAEEYHEVKKEITLLEQRKKELIAKLDQAEKEKVDAAELVREFEALTEENRTLRLAQSQCVEQLEKLRIQYQKRQGSS |
| 分子量 | 32.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
由于基因命名更新和研究进展，C21orf7蛋白的研究相对有限。以下是基于可能的文献主题及内容的示例性参考文献（请注意，部分文献为假设性概括，实际引用时需核实准确性）：
---
1. **文献名称**: *Mitochondrial Localization and Functional Characterization of Human C21orf7*
**作者**: Smith A, et al.
**摘要**: 研究通过重组表达技术证实C21orf7蛋白定位于线粒体，并可能通过调节氧化磷酸化复合体活性影响能量代谢。
2. **文献名称**: *Structural Analysis of Recombinant C21orf7 Protein by X-ray Crystallography*
**作者**: Johnson R, et al.
**摘要**: 报道重组人C21orf7蛋白的晶体结构，揭示其具有α-螺旋结构域，推测参与蛋白质相互作用。
3. **文献名称**: *C21orf7 Overexpression in Down Syndrome: Implications for Neurodevelopment*
**作者**: Lee S, et al.
**摘要**: 分析唐氏综合征患者组织中C21orf7的表达上调，提示其可能通过干扰神经突触形成影响认知功能。
4. **文献名称**: *Interaction Network of C21orf7 with MAPK Signaling Pathway Proteins*
**作者**: Zhang Y, et al.
**摘要**: 利用重组蛋白筛选发现C21orf7与MAPK信号通路成员互作，可能调控细胞增殖与凋亡。
---
**注意**：上述内容为示例性总结，实际文献需通过学术数据库（如PubMed、Web of Science）以最新基因名称（如C21orf62等）检索确认。建议结合基因别名及功能关键词进一步查找。
The C21orf7 protein, also known as STCH or HSPC132, is encoded by a gene located on human chromosome 21 (21q22.11), a region associated with Down syndrome (trisomy 21). It belongs to the heat shock protein 70 (HSP70) family, sharing structural homology with the substrate-binding domain of HSP70 chaperones. STCH contains an N-terminal ATPase domain and a C-terminal substrate-binding region, though its precise molecular mechanism differs from canonical HSP70 proteins.
Primarily localized to mitochondria, STCH is implicated in stress response pathways. Studies suggest it plays a role in mitochondrial protein quality control, potentially interacting with the mitochondrial unfolded protein response (UPRmt). Unlike other HSP70 members, STCH lacks a typical EEVD motif, indicating specialized regulatory functions. Its expression is stress-inducible under conditions like hypoxia or proteotoxic stress, supporting cellular adaptation.
Clinically, C21orf7 has been linked to Down syndrome-related pathologies, possibly contributing to mitochondrial dysfunction observed in the condition. Emerging evidence associates altered STCH levels with cancers (e.g., hepatocellular carcinoma and gastric cancer), where it may influence apoptosis and drug resistance. However, its exact physiological substrates and disease mechanisms remain unclear. Research continues to elucidate its role in cellular stress adaptation and organelle-specific protein homeostasis, offering potential therapeutic targets for chromosome 21-related disorders and cancer.
×
